导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 4.50% | 1476/4773 |
| 近一周 | -0.95% | 2276/5462 |
| 近一月 | -3.24% | 2664/5421 |
| 近一季 | -8.29% | 2889/5209 |
| 近半年 | -4.15% | 3035/4920 |
| 近一年 | 8.14% | 1353/4366 |
| 近两年 | 70.85% | 1010/2954 |
| 近三年 | 36.53% | 887/2253 |
| 成立以来 | 52.57% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
1.88% 1148/4961 |
18.48% 1374/5312 |
- - |
- - |
| 2025 | 30.43% 1321/4813 |
2.04% 1482/3635 |
1.99% 1957/4076 |
24.70% 1443/4524 |
0.49% 1974/4813 |
| 2024 | 5.07% 1852/3463 |
-2.83% 1440/2808 |
-5.12% 1653/3014 |
15.33% 1749/3129 |
-1.19% 1618/3463 |
| 2023 | -5.42% 736/2656 |
7.45% 572/2280 |
-3.95% 981/2385 |
-4.12% 1066/2515 |
-4.43% 1026/2655 |
| 2022 | -17.74% 624/2207 |
-13.23% 718/1919 |
3.37% 1164/2016 |
-10.51% 417/2113 |
2.49% 916/2208 |
| 2021 | 20.31% 182/1822 |
-1.07% 425/1255 |
10.92% 421/1330 |
6.10% 243/1466 |
3.34% 451/1822 |
| 2020 | 27.66% 575/1250 |
-3.65% 314/1028 |
15.47% 497/1067 |
10.82% 510/1164 |
3.54% 907/1184 |
| 2019 | 27.59% 540/1092 |
30.92% 223/754 |
-9.27% 643/804 |
0.73% 474/850 |
6.63% 578/918 |
| 2018 | -29.98% 459/834 |
- - |
- - |
- - |
-11.92% 385/691 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 汇添富中证500指数(LOF)C VS. 长安沪深300非周期A(740101) |